What Challenges Exist in Utilizing HLA Class II for Cancer Treatment?
Despite the promising role of HLA Class II in cancer treatment, several challenges remain. Tumors may develop mechanisms to evade immune detection, such as downregulating HLA Class II expression or inducing immune tolerance. Moreover, the high polymorphism of HLA genes complicates the development of universal treatments, as therapies may need to be tailored to individual HLA types. Additionally, while enhancing HLA Class II expression can improve immune response, it may also increase the risk of autoimmunity, where the immune system mistakenly attacks healthy cells.
